A B S T R A C T Peripheral blood lymphocytes and splenocytes of patients with autoimmune disease were used to prepare human-human hybridomas that produce autoantibodies. Because exogenous immunization was not used, the hybridoma antibodies were derived from B cells that spontaneously produced autoantibodies. 108 hybrids grew from 4,254 wells (2.5%). Optimal conditions for obtaining hybridomas with the GM 4672 myeloma line included initial growth in 2-ml wells, the use of 44% polyethylene glycol, a mononuclear cell/GM 4672 cell ratio of 5:1, and prior stimulation of the B lymphocytes with pokeweed mitogen. Hybridoma supernatants had activity against ssDNA, platelets, and erythrocytes. The results demonstrate the feasibility of producing human-human hybridomas from lymphocytes of patients with various autoimmune diseases.
INTRODUCTION
Conventional applications of hybridoma technology require the stimulation of antibodies by immunization with heterologous or allogeneic antigens, but the technique can also apply to autoantibodies that arise without deliberate immunization. Autoantibodies that have been produced by hybridomas include those against erythrocytes (1), thymocytes (2) , ribosomal RNA (3), DNA (4) , and the Sm antigen (5) . Heretofore, the method has been confined to mice with spontaneous systemic lupus erythematosus (e.g., NZB, B/W, and MRL-lpr/lpr). In our study we demonstrate the feasibility of producing human-human hybridomas that secrete autoantibodies, and we define conditions required for the derivation of stable autoantibody-producing clones from both spleen and peripheral blood lymphocytes of patients with autoimmune disease.
Received for publication 18 Fusion. Mononuclear cells were fused with 107 GM 4672 cells in ratios of 5:1 and 10:1 by the polyethylene glycol (PEG) method (7) . PEG 1540 (mol wt 1,300-1,600, J. T. Baker Chemical Co., Phillipsburg, NJ), was used at 23°C in concentrations of 38, 44, or 50% (vol/vol in RPMI 1640/ Hepes). The mononuclear and GM 4672 cells were copelleted by centrifugation, and 2 ml of 38% PEG were added. The cell pellet was gently resuspended and then sedimented by centrifugation for 5 min at 200 g. In the case of 44% PEG, 0.5 ml of PEG was added to the cell pellet. The pellet was gently resuspended and then sedimented by centrifugation for 3 min at 300 g. In the case of 50% PEG, 0.5 ml of PEG was added to the cell pellet. The pellet was gently resuspended in the 0.5 ml of PEG, and after 1 and 3 min it was sequentially diluted by addition of 0.5 ml and then 1 ml of RPMI 1640/Hepes. The cells were then spun for 5 min at 200 g. After treatment of cells with PEG, the supernatants were aspirated, and the cells were resuspended in RPMI 1640/Hepes containing 15% fetal calf serum. After incu-bation for 24 h (370C, 5% CO2), the cells were pelleted, and the tissue culture fluid was replaced with HAT medium (8) supplemented with insulin (0.5 U/ml), oxaloacetic acid (0.132 mg/ml) and 5% NCTC 109 (Microbiological Associates, Walkersville, MD). The cells were seeded into either 0.2-or 2.0-ml wells of plastic culture plates (Costar, Data Packaging, Cambridge, MA) in a concentration of 2 X 105 cells/well. The HAT medium was replaced every 5 d. 1 wk after hybrids were observed macroscopically (generally 4 wk after fusion), feeding was continued with hypoxanthine-thymidine medium. 1 wk later, the supernatants were tested for antibody production. Positive growths were cloned by limiting dilution in medium without hypoxanthine-thymidine in 0.2-ml wells of plastic culture plates. The cloned cells were fed every 7 d, and growth was usually visible after 2 wk. Subsequent cell culture was performed in vertical 75-ml flasks.
Autoantibody screening. Anti-DNA antibodies. An enzyme-linked immunoassay (ELISA) technique was used. Polystyrene plates with 96 flat-bottom wells (Dynatech Laboratories, Inc., Dynatech Corp., Alexandria, VA) were coated first with poly-L-lysine (50 Mg/ml), then with calf thymus ssDNA (2.5 Mg/ml) prepared as described (9), and finally with poly-L-glutamate (50 Mg/ml). Hybridoma supernatant (150 ul) was added to each well, and the plates were incubated for 1 h at room temperature. After washing with phosphate-buffered saline-Tween, 150 Il alkaline-phosphataseconjugated goat anti-human immunoglobulin (IgG+IgM) was added. Plates were then incubated for 18 h and washed again. Bound alkaline-phosphatase conjugate was detected by addition of 150 ul p-nitrophenyl phosphate (1 mg/ml in 0.5 M NaHCO3, 2 mM MgCI2, pH 9.5) at 23°C. The reaction was stopped with 5 N NaOH, and optical densities were read at 405 nm in a Dynatech model MR580 Micro ELISA Reader.
Antiplatelet antibodies. Platelets obtained from citrated blood were fixed with 3% glutaraldehyde, washed twice with Tris-buffered saline, and stored in 60% glycerol at -20°C. Before use, the platelets were resuspended in 2 vol of Tris-buffered saline (TBS), sedimented at 500 g for 15 min, and resuspended in TBS at a concentration of 0.5-1 X 10' cells/ml. A 100-Ml aliquot of the platelet suspension was added to flat-bottom microtiter wells, and the platelets were sedimented by centrifugation at 1,000 g for 5 min. After aspiration of the supernatant, 200 Ml of TBS with 0.5% gelatin was added to each well and the plate was incubated at 370C for 30 min. The wells were washed thrice with TBS, hybridoma supernatant was added, and the plate was incubated at 370C for 60 min. After washing with TBS, 100 ul of alkaline phosphatase-conjugated goat antihuman immunoglobulin was added. The remainder of the assay was carried out as above.
Cold agglutinin. Hybridoma culture fluid (100 ;l) was incubated with a 2% suspension of washed, ficin-treated, type 0 erythrocytes for 1 h at 4°C. The suspensions were examined for hemagglutination. Of the 108 hybridomas, 16 produced autoantibodies. All of them had the IgM isotype. Seven primary growths produced antibodies to ssDNA. All seven were cloned by limiting dilution, and in each case the procedure yielded multiple antibody-producing clones. with autoimmunity, the frequency of autoantibodyproducing hybridomas was 16/65 (25%), a figure that to bind to ssDNA. Preliminary results of compares favorably with the proportion in MRL-lpr/ ling and competitive immunoassays (data lpr mice (9-58% in various experiments (4)). The indicated that all clones derived from a amount of autoantibody produced by the human-huary growth gave identical or similar pat-man hybridomas ranged from 1 to 15 ug IgM/ml (data activity. Therefore, the primary growths not shown), whereas mouse-mouse hybridomas usually bly derived from single hybridomas.
RESULTS
secrete 50-100 jsg autoantibody/ml. Optimal conditry wells contained antiplatelet activity and tions for obtaining hybridomas with the GM 4672 line toned by limiting dilutions. That procedure include initial growth in 2.0-ml wells, the use of 44% 0 clones, 37 of which produced platelet-PEG, a mononuclear cell/GM 4672 cell ratio of 5:1, tibodies (Fig. 1B) . The supernatants of the and prior stimulation of the lymphocytes with PWM. ine had no antibody binding activity with The latter step, we believe, favors the fusion of auDr did human-human hybrids derived from toantibody-forming B lymphocytes with GM 4672 zs from a patient without autoimmune cells. A PEG concentration of 50% was apparently topenia. As a positive control for the assay toxic to some cultures, and we have abandoned its use. im with anti-PLA antibodies contained an-The difference between 44 and 38% PEG may not be ctivity, whereas normal serum had no ac-statistically significant. Use of 2.0-ml wells may be advantageous by providing a relatively large surface imary growths from the patient with cold area for growth of the hybridomas. In our experience, disease (F3) produced cold agglutinins. the ELISA technique readily measures the relatively ilutions yielded 46 clones, of which 14 were low yield of autoantibody from human-human hybricold agglutinins. The supernatants of those domas. Moreover, we have found that cloned humanactive at 40C, but not at 27°or 370C, and human hybridomas grow well in vertical 150-ml flasks, vas revealed only with ficin-treated eryth-and by this means we have harvested as much as 600 ml of autoantibody-containing tissue culture fluid a cloned autoantibody-producing hybridobeen passed in tissue culture repeatedly. All of thE mas have 1 from each clone. Affinity purification on DNA-Sepharose columns of fluids that contain anti-DNA antibodies can thus yield amounts of monoclonal autoantibody that are adequate for extensive analyses (unpublished observations). Thus far, our attempts to grow human hybridomas in nude mice have been unsuccessful.
Hybridoma technology is a means of obtaining pure monoclonal autoantibodies and it has been highly effective in murine systems. The present results indicate that a similar approach is possible with human autoantibodies. These monoclonal antibodies should greatly facilitate studies of the antigen specificity and the structure of the combining site of antibodies produced in SLE and other autoimmune disorders. The technique may also find applications in the study of allergic diseases that are mediated by immunoglobulins.
